Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) derived from oxicam. Meloxicam acts by inhibition of prostaglandin synthesis exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue
Dogs – For the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders and reduction of postoperative pain and inflammation following orthopaedic and soft tissue surgery.
Cats – Reduction of pain after surgery and management of febrile conditions in combination with appropriate antibiotics.
Each mL contains 5mg Meloxicam.
Injection 10ml, 20ml multidose vial.
Directions for Use:
Use all product within 28 days of first broaching the container. Discard any unused portion.
Contraindicated for use in pregnant or lactating animals. Contraindicated for use in animals less than 6 weeks of age.
Dosage and Administration:
Musculosketeal disorders: a single subcutaneous injection 0.4mL/10kg bodyweight before surgery.
Post-operative Pain: a single intravenous or subcutaneous injection 0.4mL/10kg bodyweight before surgery.
Post-operative pain and febrile conditions: a single subcutaneous injection 0.3mL/5kg bodyweight.
Store below 30°C (room temperature). Store locked up.
Dispose of empty container by wrapping with paper and putting in the garbage.
If in eyes, rinse cautiously with water for several minutes. If eye irritation persists seek medical advice. If poisoning occurs, contact a doctor or Poisons Information Centre. Phone New Zealand 0800 764 766 (0800 POISON).
DO NOT use in pregnant or lactating animals. DO NOT use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders or where there is evidence of individual hypersensitivity to the product. As for all NSAIDs use in animals less than 6 weeks of age or in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided careful clinical management may be necessary.
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Meloxicam must not be administered in conjunction with other NSAIDs or glucocorticosteriods. Concurrent administration of potential nephrotoxic drugs should be avoided.
Pre-treatment with other anti-inflammatory drugs prior to the use of Meloxicam may result in additional or increased adverse effect and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement with Meloxicam injection. The treatment-free period however should take into account the pharmacokinetic properties of the drugs previously used
Parenteral administration of Meloxicam injection is tolerated without local adverse reactions. Typical adverse reaction of NSAIDs include loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy. These side effects are in most cases transient and disappear following termination of treatment, but in rare cases may be serious.
Hypovolaemia or hypotension should be corrected prior to use of the product.
In case of overdosing a symptomatic treatment should be initiated.
Do not handle until safety precautions have been read and understood.
Warning: Causes serious eye damage. Suspected of damaging fertility or the unborn child. If exposed or concerned get medical advice.
Handling Precautions: Wash hands thoroughly after handling. Wear eye protection.
Registered pursuant to the ACVM Act 1997, No A10639
RESTRICTED VETERINARY MEDICINE
Meloxicam Injection For Animal Treatment Only